Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This study investigated factors predicting the resumption of mirabegron following its discontinuation with successful treatment of overactive bladder (OAB).
Methods: In all, 374 OAB patients reporting an improvement in subjective symptoms after a minimum of 3 months treatment with mirabegron 25 mg, q.d., were screened. Those wanting to continue with the medication (n = 109) were excluded from the study. The remaining 265 patients discontinued mirabegron and their outcomes were evaluated at baseline (discontinuation) and 1, 3, 6, 9, and 12 months using the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), Urgency Severity Scale (USS), Patient's Perception of Bladder Condition (PPBC), and Global Response Assessment (GRA), as well as uroflowmetry and post-void residual (PVR).
Results: After mirabegron discontinuation, 203 patients completed follow-up. The mean (±SD) duration from discontinuing medication to resumption of mirabegron was 2.25 ± 1.17 months (range 1-12 months). Compared with the 111 (54.7%) patients who did not resume mirabegron, the 92 (45.3%) patients who resumed mirabegron had a higher USS at time of discontinuation (1.18 ± 1.76 vs. 0.65 ± 1.33; P = 0.017). The USS was a strong predictor of mirabegron resumption (P = 0.02; odds ratio 1.315; 95% confidence interval 1.051-1.646).
Conclusions: Among OAB patients who were successfully treated with mirabegron for ≥3 months, nearly half requested resumption of mirabegron after discontinuation. A higher USS was found to predict retreatment after discontinuation of mirabegron in OAB patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/luts.12252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurogenic Voiding Dysfunction in Spinal Cord Injury and Stroke: Urodynamic Evaluation, Functional Classification, and Therapeutic Strategies.
Cureus
August 2025
General Medicine, Universidad de Ciencias Médicas (UCIMED), San José, CRI.
Many patients with injuries to their central nervous system, especially those who have had a stroke or a spinal cord injury, have neurogenic voiding dysfunction. It happens when patients can't control their bladder voluntarily, which can make them feel urgency, experience leaks, or have trouble emptying their bladder. If not treated right away, it can cause infections, damage to the bladder, or even kidney problems over time.
View Article and Find Full Text PDFSystemic Immune-Inflammation Index and Neutrophil-To-Lymphocyte Ratio: U-Shaped Association With Overactive Bladder.
Low Urin Tract Symptoms
September 2025
Department of Urology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Objectives: This study aims to examine the association of systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with the prevalence of overactive bladder (OAB).
Methods: This cross-sectional study analyzed data from 22,343 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (2005-2018). We applied weighted multivariate logistic regression, restricted cubic spline (RCS) regression, subgroup, and sensitivity analyses to assess the associations between SII, NLR, and OAB.
Fear of falling, gait capacity, and dual task performance in multiple sclerosis patients with and without neurogenic overactive bladder.
Acta Neurol Belg
September 2025
Department of Neurology, Kutahya Health Sciences University, Kütahya, Turkey.
Background: Overactive bladder (OAB) symptoms significantly affect the independence and quality of life in patient with multiple sclerosis (PwMS) by limiting daily activities. This study aimed to explore differences in fear of falling (FoF), gait, dual-task performance, and self-perceived impact of disease among PwMS with and without OAB.
Method: Participants were divided into two groups based on their Overactive Bladder Questionnaire (OAB-V8) scores: OAB (score ≥ 8) and non-OAB (score < 8).
Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality.
Anal Bioanal Chem
September 2025
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt.
The recent approval of a fixed-dose combination of silodosin (SOD) and solifenacin succinate (SOF) for overactive bladder syndrome has created a need for innovative analytical approaches enabling their simultaneous quantification. In this work, seven novel, eco-friendly, and cost-efficient spectrophotometric methods were developed for the concurrent determination of SOD and SOF. These methods overcome the limitations of conventional techniques by eliminating the need for complex instrumentation, labor-intensive procedures, and large volumes of hazardous organic solvents, offering a sustainable and accessible analytical alternative.
View Article and Find Full Text PDFClinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial.
Urology
September 2025
Sumitomo Pharma America, Inc., Marlborough, MA.
Objective: To demonstrate the impact of vibegron treatment in the phase 3 COURAGE trial (NCT03902080) on clinically meaningful response parameters in men with overactive bladder (OAB) receiving pharmacological therapy for benign prostatic hyperplasia (BPH) as measured by standard, validated patient-reported outcomes.
Methods: Men >45 years with OAB receiving pharmacotherapy for BPH were randomly assigned 1:1 to vibegron 75 mg or placebo for 24 weeks. Participants completed bladder diaries assessing changes in micturition frequency, nocturia, and urge urinary incontinence (UUI); International Prostate Symptom Score (IPSS); and OAB questionnaire (OAB-q).